Vertex Pharmaceuticals
VRTX
500 hedge funds and large institutions have $28.5B invested in Vertex Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 185 increasing their positions, 181 reducing their positions, and 36 closing their positions.
69% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 36
4% more funds holding
Funds holding: 479 → 500 (+21)
3% more capital invested
Capital invested by funds: $27.5B → $28.5B (+$933M)
2% more repeat investments, than reductions
Existing positions increased: 185 | Existing positions reduced: 181
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
35% less call options, than puts
Call options by funds: $86.7M | Put options by funds: $134M
Top Buyers
Top Sellers
VRTX Hedge Fund Activity: Q2 2015 in Review
500 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2015, worth a combined $28.5B — up 3.4% from $27.5B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new VRTX positions and 36 closed out — a net gain of 25 holders — while 185 added to existing stakes and 181 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $140M. The largest seller was Wellington Management Group, cutting an estimated $187M.
- 500 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2015, up from 479 in Q1 2015.
- Funds reported $28.5B of Vertex Pharmaceuticals stock for Q2 2015, up 3.4% quarter-over-quarter.
- 61 funds opened new Vertex Pharmaceuticals positions in Q2 2015 and 36 closed out, a net change of +25 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2015 was Fidelity Investments, an estimated $140M added.
- The largest Vertex Pharmaceuticals seller in Q2 2015 was Wellington Management Group, an estimated $187M sold.
Based on aggregated 13F filings for Q2 2015.